Tuesday, March 19, 2019 -- Stephanie Hathaway with her daughters Brenley, left, and Hadley, in South Windsor, Conn.
Friday, March 15, 2019 -- NST Basic DVD Training - Lumbar Spine from Michael Nixon-Livy on Vimeo.By Dr. Michael Nixon-Livy Overview Without doubt lower back pain is one of modern man's most frequent, challenging and unrelenting problematic health conditions. In this age of modern medical and scientific research, new discoveries are being made at a rapid rate; yet, nothing is emerging to quell the seemingly worsening state of affairs accompanying the undeniable fact that this global health condition is on the increase. Some salient information: Approximately 80 percent of the world's population, ranging from adolescents to the elderly will suffer from lower back pain — LBP at some point in their lives. Currently 1 person in 10 is suffering from LBP, making it the
Thursday, March 14, 2019 -- The herb saffron may be a safe and effective treatment for attention deficit hyperactivity disorder (ADHD).1 This common neuropsychiatric disorder affects up to 7 percent of school-age children, causing a mix of symptoms including difficulty concentrating and hyperactivity to mood swings and short attention span. In up to 60 percent of cases, symptoms persist into adulthood,2 where the disorder is linked to social problems, low self-esteem and low quality of life. It’s also known to affect academic achievement. The standard, first-line approach to treating ADHD is medication, typically central nervous system stimulants such as methylphenidate (Ritalin). However, such drugs may cause side effects such as difficulty sleeping, loss of appetite and nausea. In some cases, the side effects, such
Tuesday, March 19, 2019 -- The FDA has granted an approval to the combination of atezolizumab with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer.
Thursday, March 14, 2019 -- by Ligia Traldi Macedo, Vinicius Eduardo Ferrari, Juliana Carron, Ericka Francislaine Dias Costa, Leisa Lopes-Aguiar, Gustavo Jacob Lourenço, Carmen Silvia Passos Lima Background Chemotherapy-induced nausea and vomiting are concerning adverse events resulting from cancer treatment, and current guidelines recommend the use of neurokinin-1-selective antagonists, such as fosaprepitant, in highly emetogenic schemes. However, the implementation of this strategy may be limited by the cost of treatment. GSTP1 c.313A>G genotype was recently described as a predictor of vomiting related to high-dose cisplatin. We hypothesized that the inclusion of routine GSTP1 c.313A>G screening may be promising in financial terms, in contrast to the wide-spread use of fosaprepitant. Methods A cost-minimization analysis was planned to compare GSTP1 c.313A>G genotyping versus overall fosaprepitant implementation
Tuesday, March 19, 2019 -- Just a week after Roche’s Tecentriq became the first immuno-oncology agent the FDA approved for triple-negative breast cancer, the anti-PD-L1 drug has clinched another first-in-class approval—this time in lung cancer.
Friday, March 15, 2019 -- Increased consumption of eggs and dietary cholesterol is linked to a significantly higher risk of cardiovascular disease and death, according to a new study.
Thursday, March 14, 2019 -- (Natural News) A study reports that acupuncture is as effective as nicotine replacement therapy in helping people stop smoking. The study, which was published in the journal Chest, aimed to assess the efficacy of acupuncture, auricular point pressing, and nicotine replacement therapy on tobacco cessation in the Chinese population. For the study, a team of... Read More
Monday, March 18, 2019 -- A high dose of Amarin Corp's Omega-3 drug Vascepa significantly reduced the occurrence of first and subsequent heart attacks, strokes and other serious heart problems in high-risk patients already taking cholesterol medication by even more than initially reported, according to data presented on Monday.
Friday, March 15, 2019 -- Healthy British adults who reported consuming little or no red meat were 11% to 36% less likely to develop type 2 diabetes during nearly 2 decades of follow-up vs. a large sample of red meat eaters, according to findings published in Nutrition & Diabetes.“Our results indicate that low- and non-meat diets are associated with a lower risk of diabetes in this population,” Keren Papier, PhD, a nutritional epidemiologist in the cancer epidemiology unit at the University of Oxford, United Kingdom, and colleagues wrote. “Lower BMI in low- and non-meat eaters appears to be at
Thursday, March 14, 2019 -- Healthy pregnant women with and without polycystic ovary syndrome experience similar rates of adverse obstetric outcomes, likely due to women with PCOS following a healthier lifestyle, according to findings published in Clinical Endocrinology.In a multicenter analysis of pregnant women across four countries, researchers also found that women with PCOS had a 38% lower risk for delivering a baby large for gestational age than women without PCOS.“These findings highlight that following a healthy lifestyle may compensate for the risk of having PCOS for pregnancy complications,” Lisa
Friday, March 15, 2019 -- by João Luiz Miraglia, Ana Carolina Cintra Nunes Mafra, Camila Nascimento Monteiro, Luciana Morais Borges Background Noncommunicable diseases (NCDs) were responsible for 72.3% of global deaths in 2016, with cardiovascular diseases accounting for almost half of those deaths and low- and middle-income countries carrying the biggest burden. As a result, the prevention and control of NCDs is recognized as urgent, while better surveillance at the country level could result in more effective policies. Hence, the objective of this study was to obtain more detailed information on the distribution of the prevalence of hypertension and diabetes among the population of two large districts of the city of São Paulo in Brazil, and to compare these findings to the results of
Monday, March 18, 2019 -- There have been more than a dozen blood pressure drug recalls since 2018.
Thursday, March 14, 2019 -- Lupin has indicated it has received another FDA warning letter as regulatory issues continue to pile up for the Indian drugmaker. The most recent letter comes just four months after the agency issued a two-plant warning and told the drugmaker it needs to evaluate its entire manufacturing system because it keeps repeating mistakes.
Monday, March 18, 2019 -- After AstraZeneca released overall CV outcomes results for Farxiga, the company has dug further into the data and presented two subanalyses on Monday.
Friday, March 15, 2019 -- Type 2 diabetes increases the risk for obstructive sleep apnea in adults, and obesity, diabetes-related foot disease and depression are among the risk factors for the condition, according to findings published in Diabetes Care.“Cross-sectional and cohort studies have shown that OSA is associated with worse glycemic control in patients with type 2 diabetes and with diabetes-related vascular complications,” G. Neil Thomas, PhD, professor in epidemiology and research methods in the Institute of Applied Health Research at the University of Birmingham in the U.K., and colleagues wrote.
Friday, March 15, 2019 -- The U.S. Food and Drug Administration has granted accelerated approval to a combination of Tecentriq (atezolizumab) and the chemotherapy Abraxane (nab-paclitaxel) for patients with advanced triple-negative breast cancer, making this the first immunotherapy regimen approved specifically for breast cancer. The approval, which is for patients whose tumors produce the PD-L1 factor and are unable to receive […] The post FDA Grants Accelerated Approval to Tecentriq-Abraxane Combo for Some TNBC appeared first on Breast Cancer News.
Tuesday, March 19, 2019 -- In two clinical trials, combination treatments that included an immune checkpoint inhibitor and axitinib (Inlyta) led to better outcomes for patients with advanced kidney cancer than treatment with sunitinib (Sutent), the standard initial therapy.
Monday, March 18, 2019 -- European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
Tuesday, March 19, 2019 -- The novel HeartMate 3 pump is superior to the HeartMate II pump and the magnitude of benefit is large with a Number Needed to Treat (NNT) of <1. Continue reading →